Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07593391 · ClinicalTrials.gov registry record · Phase 3
An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
A Phase 3 study, sponsored by Neuren Pharmaceuticals Limited.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 180
- Enrollment target
NCT07593391 is a Phase 3 study that is actively recruiting participants, run by Neuren Pharmaceuticals Limited. The registered enrollment target is 180 participants.
The verdict
NCT07593391, a Phase 3 study, is actively recruiting participants, sponsored by Neuren Pharmaceuticals Limited.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 180 participants
- Enrollment target
Study Summary
This Phase 3, open-label extension, multicenter study will evaluate long-term safety, tolerability and efficacy of NNZ-2591 in pediatric participants with Phelan- McDermid Syndrome.
Interventions
- DRUG NNZ-2591
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2026-05-20 |
| Est. Completion | 2028-11-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07593391
The ClinicalTrials.gov registry entry for NCT07593391 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neuren Pharmaceuticals Limited, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NNZ-2591 is the first listed.
NCT07593391 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07593391 about?
NCT07593391 is a clinical study titled "An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome". This Phase 3, open-label extension, multicenter study will evaluate long-term safety, tolerability and efficacy of NNZ-2591 in pediatric participants with Phelan- McDermid Syndrome.
What is the current status of trial NCT07593391?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2026-05-20. Estimated completion is 2028-11-12.
What interventions are being tested in trial NCT07593391?
The interventions under investigation include: NNZ-2591 (DRUG).
Who is sponsoring clinical trial NCT07593391?
This trial is sponsored by Neuren Pharmaceuticals Limited, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.